2-[3-[[(1S,2R,3R,4R)-3-(acetyloxymethyl)-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]acetic acid | 127980-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[3-[[(1S,2R,3R,4R)-3-(acetyloxymethyl)-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]acetic acid
• CAS: 127980-35-2
• 化学式: C₁₈H₂₂O₅
• 分子量: 318.37
• InChiKey: WTJPLXVRUFCMSG-LTIDMASMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[3-[[(1S,2R,3R,4R)-3-(acetyloxymethyl)-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]acetic acid 在 盐酸 、 sodium hydroxide 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.75h， 生成 [3-((1S,2R,3S,4R)-3-Formyl-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-acetic acid methyl ester
  参考文献：
  名称：

  间亚苯基7-氧杂双环[2.2.1]庚烷血栓烷A2拮抗剂。Semicarbazoneω-链。

  摘要：

  制备了一系列手性联苯间7-氧杂双环[2.2.1]庚烷半咔唑酮19-26，并对其体外血栓烷（TxA2）拮抗活性和体内作用时间进行了评估。发现19-26的效力高度依赖于亚间苯环的取代模式，并且以大于间位大于邻位的顺序降低。SQ 35,091（25），[1S-（1 alpha，2 alpha，3 alpha，4 alpha）]-2-[[3-[[[[（（苯基氨基）羰基]肼基]甲基] -7-氧杂双环[2.2.1 [庚基-2-基]甲基]苯丙酸被鉴定为有效且长效的TxA2拮抗剂。在富含人血小板的血浆中，SQ 35,091抑制了花生四烯酸（800 microM）和U-46,619（10 microM）诱导的聚集，I50值分别为3和12 nM。相反，大于1000 microM时未观察到对ADP（20 microM）诱导的聚集的抑制。用[3H] -SQ 29,548进行的受体结合研究表明，SQ 35,091是

  DOI：

  10.1021/jm00113a030
• 作为产物：
  描述：

  [(1R,2R,3R,4S)-3-(3-{2-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-ethyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol 在 吡啶 、 chromium(VI) oxide 、 4-二甲氨基吡啶 、 硫酸 作用下， 以 丙酮 为溶剂， 反应 4.0h， 生成 2-[3-[[(1S,2R,3R,4R)-3-(acetyloxymethyl)-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]acetic acid
  参考文献：
  名称：

  间亚苯基7-氧杂双环[2.2.1]庚烷血栓烷A2拮抗剂。Semicarbazoneω-链。

  摘要：

  制备了一系列手性联苯间7-氧杂双环[2.2.1]庚烷半咔唑酮19-26，并对其体外血栓烷（TxA2）拮抗活性和体内作用时间进行了评估。发现19-26的效力高度依赖于亚间苯环的取代模式，并且以大于间位大于邻位的顺序降低。SQ 35,091（25），[1S-（1 alpha，2 alpha，3 alpha，4 alpha）]-2-[[3-[[[[（（苯基氨基）羰基]肼基]甲基] -7-氧杂双环[2.2.1 [庚基-2-基]甲基]苯丙酸被鉴定为有效且长效的TxA2拮抗剂。在富含人血小板的血浆中，SQ 35,091抑制了花生四烯酸（800 microM）和U-46,619（10 microM）诱导的聚集，I50值分别为3和12 nM。相反，大于1000 microM时未观察到对ADP（20 microM）诱导的聚集的抑制。用[3H] -SQ 29,548进行的受体结合研究表明，SQ 35,091是

  DOI：

  10.1021/jm00113a030

文献信息

• Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists
  作者：Raj N. Misra、Baerbel R. Brown、Philip M. Sher、Manorama M. Patel、Steven E. Hall、Wen Ching Han、Joel C. Barrish、Octavian Kocy、Don N. Harris

  DOI：10.1021/jm00062a013

  日期：1993.5

  A series of interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles (2) were prepared and evaluated for their thromboxane (TxA2) antagonistic activity in vitro and duration of action in vivo. Examination of the carboxyl side chain indicated that the interphenylene ring substitution pattern and, to a lesser extent, chain length were important factors in determining TxA2 antagonistic potency. For the carboxyl side chain, ortho substitution, a single methylene spacer between the interphenylene and oxabicycloheptane rings, and a propionic acid side-chain length were determined to be optimal. With respect to the oxazole side chain a wide range of amide substituents with diverse structures and lipophilicities were compatible with potent antagonistic activity. Finally. an acidic functional group on the alpha-chain and a hydrogen bond acceptor on the 4-position of the oxazole ring were critical for potent activity. From the analogs prepared 42 BMS-180,291: [(+)-1S-(1alpha,2alpha,3alpha,4alpha)]-2-[[3-[4-[(n-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid} was found to be a potent, selective, and orally-active TxA2 antagonist with a long duration of action and has been selected as a candidate for clinical development. In human platelet-rich plasma, 42 inhibited arachidonic acid (800 muM) and U-46,619 (10 muM) induced aggregation with I50 values of 7 and 21 nM, respectively. Radioligand binding studies of 42 with [H-3]-SQ 29,548 showed a K(d) value of 4.0 +/- 1.0 nM in human platelet membranes. Both in vitro and in vivo studies indicated 42 was devoid of direct agonistic activity. In vivo 42 (0.2 mg/kg, po) showed extended protection (T50 = 14.4 h) from U-46,619 (2 mg/kg, iv) induced death in mice, and a single oral dose of 42 (3 mg/kg) abolished U46,619-induced platelet aggregation ex vivo in African green monkeys for >24 h.